ES2608923T3 - Métodos y composiciones para aumentar la sensibilidad a los inhibidores de la tirosina quinasa - Google Patents

Métodos y composiciones para aumentar la sensibilidad a los inhibidores de la tirosina quinasa Download PDF

Info

Publication number
ES2608923T3
ES2608923T3 ES10832418.7T ES10832418T ES2608923T3 ES 2608923 T3 ES2608923 T3 ES 2608923T3 ES 10832418 T ES10832418 T ES 10832418T ES 2608923 T3 ES2608923 T3 ES 2608923T3
Authority
ES
Spain
Prior art keywords
egfr
tyrosine kinase
mirna
expression
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10832418.7T
Other languages
English (en)
Spanish (es)
Inventor
Peter Jeffery Leedman
Keith Michael Giles
Felicity Caris Kalinowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009905758A external-priority patent/AU2009905758A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Application granted granted Critical
Publication of ES2608923T3 publication Critical patent/ES2608923T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES10832418.7T 2009-11-24 2010-11-24 Métodos y composiciones para aumentar la sensibilidad a los inhibidores de la tirosina quinasa Active ES2608923T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009905758 2009-11-24
AU2009905758A AU2009905758A0 (en) 2009-11-24 Method of Modulating Epidermal Growth Factor (EGF) Ligands
PCT/AU2010/001578 WO2011063456A1 (en) 2009-11-24 2010-11-24 Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2608923T3 true ES2608923T3 (es) 2017-04-17

Family

ID=44065735

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10832418.7T Active ES2608923T3 (es) 2009-11-24 2010-11-24 Métodos y composiciones para aumentar la sensibilidad a los inhibidores de la tirosina quinasa

Country Status (9)

Country Link
US (2) US9051551B2 (https=)
EP (2) EP2521555B1 (https=)
JP (2) JP2013511559A (https=)
CN (2) CN102762214A (https=)
AU (2) AU2010324529A1 (https=)
CA (2) CA2781571A1 (https=)
DK (1) DK2521555T3 (https=)
ES (1) ES2608923T3 (https=)
WO (2) WO2011063455A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
NZ704322A (en) * 2010-07-06 2016-07-29 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
JP6342329B2 (ja) * 2011-11-25 2018-06-13 アンテグラジャンＩｎｔｅｇｒａｇｅｎ Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法
FR2984168B1 (fr) * 2011-12-19 2019-07-05 Chanel Parfums Beaute Micro-rna pour leur utilisation dans la pigmentation
US20150126621A1 (en) * 2012-05-15 2015-05-07 New York University METHOD FOR PREDICTING RECURRENCE OF MELANOMA USING miRNA ALTERATIONS
WO2014059484A1 (en) * 2012-10-18 2014-04-24 The University Of Western Australia CANCER THERAPY USING miRNAs
CN105263523A (zh) * 2013-03-15 2016-01-20 米尔纳疗法公司 使用微rna和egfr-tki抑制剂的联合癌症治疗
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
CA2919477A1 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
CN108537001B (zh) * 2018-04-12 2021-06-01 华中科技大学鄂州工业技术研究院 一种预测用于治疗肝癌的特异性治疗药物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511678A (ja) * 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロｒｎａによるオンコジーンの調節
CA2857881A1 (en) * 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
ES2534430T3 (es) * 2006-08-28 2015-04-22 The University Of Western Australia Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN
DK2104737T3 (da) * 2006-12-08 2013-05-27 Asuragen Inc Funktioner og formål for let-7 mikro-RNAer
US20100173954A1 (en) * 2007-01-19 2010-07-08 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents

Also Published As

Publication number Publication date
US20130116299A1 (en) 2013-05-09
US9051551B2 (en) 2015-06-09
EP2521555B1 (en) 2016-09-28
EP2504014A1 (en) 2012-10-03
US20130090366A1 (en) 2013-04-11
AU2010324529A1 (en) 2012-07-19
EP2521555A1 (en) 2012-11-14
EP2521555A4 (en) 2013-08-07
CA2781572A1 (en) 2011-06-03
CN102762213A (zh) 2012-10-31
JP2013511559A (ja) 2013-04-04
CA2781571A1 (en) 2011-06-03
AU2010324530A1 (en) 2012-07-19
JP2013511560A (ja) 2013-04-04
EP2504014A4 (en) 2013-04-17
WO2011063456A1 (en) 2011-06-03
AU2010324530B2 (en) 2016-12-15
DK2521555T3 (en) 2017-01-09
CN102762214A (zh) 2012-10-31
WO2011063455A1 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
ES2608923T3 (es) Métodos y composiciones para aumentar la sensibilidad a los inhibidores de la tirosina quinasa
Eggers et al. microRNA miR-200b affects proliferation, invasiveness and stemness of endometriotic cells by targeting ZEB1, ZEB2 and KLF4
Wu et al. Lnc RNA TPT 1‐AS 1 promotes tumorigenesis and metastasis in epithelial ovarian cancer by inducing TPT 1 expression
Medici et al. Snail and Slug promote epithelial-mesenchymal transition through β-catenin–T-cell factor-4-dependent expression of transforming growth factor-β3
Huang et al. miR-340 suppresses glioblastoma multiforme
Yan et al. miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer
Bao et al. A TrkB–STAT3–miR-204-5p regulatory circuitry controls proliferation and invasion of endometrial carcinoma cells
Lv et al. LncRNA PINK1-AS promotes Gαi1-driven gastric cancer tumorigenesis by sponging microRNA-200a
Zhu et al. Long non‐coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B‐cell lymphoma cells by targeting miR‐497‐5p/PIM1 axis
Lin et al. Attenuation of TGF-β signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary epithelial cells
US20140323551A1 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
Nakamichi et al. Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
Wang et al. Relation between the expression of mitotic centromere–associated kinesin and the progression of squamous cell carcinoma of the tongue
Wang et al. Downregulated miR-495 inhibits the G1-S phase transition by targeting bmi-1 in breast cancer
Wang et al. MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor
Zhou et al. MicroRNA-206 attenuates glioma cell proliferation, migration, and invasion by blocking the WNT/β-catenin pathway via direct targeting of Frizzled 7 mRNA
Barbolina et al. Microenvironmental regulation of chemokine (CXC-motif) receptor 4 in ovarian carcinoma
Chen et al. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis
Zhang et al. Overexpression of microRNA-365 inhibits breast cancer cell growth and chemo-resistance through GALNT4.
Li et al. MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.
Wang et al. PIK3CA is regulated by CUX1, promotes cell growth and metastasis in bladder cancer via activating epithelial-mesenchymal transition
WO2017217807A2 (ko) Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
Wang et al. Zeb1 regulates the symmetric division of mouse lewis lung carcinoma stem cells through numb mediated by miR-31
Li et al. RETRACTED: Pard3 suppresses glioma invasion by regulating RhoA through atypical protein kinase C/NF‐κB signaling
Li et al. MicroRNA‐125a inhibits tumorigenesis by targeting Smurf1 in colorectal carcinoma